Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy;Cardioversores-desfibrilhadores implantáveis na miocardiopatia hipertrófica

Revista Portuguesa de Cardiologia

Volumn 24, Issue 3, 2005, Pages 407-415

  Pinheiro Vieira, A ^a   Pulido Adragão, Pedro ^a   Reis Santos, Katya ^a   Bello Morgado, Francisco ^a   Magalhães Cavaco, Diogo ^a   Rossi, Renata ^a   Abecasis, Miguel ^a   Neves, José Pedro ^a   Bonhosrst, Daniel ^a   Lopes Gomes, J ^a   Seabra Gomes, Ricardo ^a  

^a NONE

Author keywords

Hypertrophic cardiomyopathy; Implantable cardioverter defibrillator; Sudden cardiac death; Ventricular arrhythmias

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEFIBRILLATOR; FAMILY HISTORY; FEMALE; GENE MUTATION; HEART ARREST; HEART LEFT VENTRICLE HYPERTROPHY; HEART PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPOTENSION; MALE; PRIMARY PREVENTION; RISK FACTOR; SCHOOL CHILD; SECONDARY PREVENTION; SUDDEN DEATH; SYNCOPE;

ADOLESCENT; ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 21044433134     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophie cardiomyopathy. Circulation 1995;92:1336-47.
2. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophie cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 1995;92:785-9.
3. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
4. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287:1308-20.
5. Klues HG. Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26:1699-708.
6. McKenna WJ, Deanfield J, Faruqui A, England D, Oakley CM, Goodwin JF. Prognosis in hypertrophie cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47:532-8.
7. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982;65:1388-94.
8. Maron BJ, McKenna WJ, Danielson GK, et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-91.
9. Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes: clinical, demographic and pathological profiles. JAMA 1996;276:199-204.
10. Primo J, Greelen P, Brugada J, et al. Hypertrophic cardiomyopathy: role of the implantable defibrillator. J Am Coll Cardiol 1998;31:1081-5.
11. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001;22:1374-450.
12. Elliott PM, Blanes JRG, Mahon NG, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357:420-4.
13. The Antiarrhythmic Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
14. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guidelines update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2002;106:2145-61.
15. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73.
16. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-8.
17. Maron BJ, Estes NA, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003 Jun 17;107(23):2872-5.